Research & Development
The spirit of innovation at Merz can be traced directly back to our company founder, who always started with the question, “What is needed?” The goal behind every new product or formulation was to respond to those needs differently and more successfully, and Merz is proud to continue this tradition today through its highly-specialized research and development programs.
More than 300 Merz employees worldwide focus on innovation and R&D activities, and approximately 100 million euros per year are dedicated to the development of additional products, new formulations and novel indications. Merz’s R&D programs are fully aligned with our global focus on aesthetics and neurotoxins, both of which represent emerging fields with considerable growth potential.
Merz Device Innovation Center: Our Values at Work
Over the past five years, Merz has successfully completed numerous acquisitions in the medical aesthetics space, bringing in technologies and talent to create a comprehensive aesthetics portfolio of toxins, fillers, energy-based devices and skincare. The development work of our internal R&D teams has enabled Merz to bring to market advanced filler- and toxin formulations, new classes of aesthetic devices and indications in all these categories, with much more to come.
At the core of Merz’s approach to neurotoxin therapy is the belief that every patient is unique and has individual therapeutic needs. Our key neurotoxin projects include research on adult lower-limb spasticity (common post-stroke syndrome), sialorrhea (excess drooling often experienced by cerebral palsy and Parkinson’s disease patients), and pediatric spasticity associated with cerebral palsy. We also continue to research flexible and individualized treatment paradigms for optimized patient outcomes.